Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.39 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.39 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.39 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577437 | 1.00 | NPC1 (0.47) | NPC1RAB9ACYP1A1CYP1B1FGFR1 | |
| SCHEMBL29577802 | 0.86 | NPC1 (0.49) | NPC1RAB9ACYP1A1CYP1B1FGFR1 | |
| SCHEMBL20332207 | 0.86 | NPC1 (0.49) | NPC1RAB9ACYP1A1CYP1B1FGFR1 | |
| SCHEMBL20330972 | 0.77 | NPC1 (0.59) | NPC1RAB9ACYP1A1CYP1B1FGFR1 | |
| SCHEMBL29428742 | 0.77 | NPC1 (0.59) | NPC1RAB9ACYP1A1CYP1B1FGFR1 | |
| SCHEMBL31753865 | 0.77 | HTT (0.45) | HTTGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8900322 | 0.72 | HTT (0.58) | CYP1A2CYP3A4CYP2C19HTTHSD17B10 | |
| SCHEMBL20331733 | 0.71 | NPC1 (0.51) | NPC1RAB9ACYP1A1CYP1B1FGFR1 | |
| SCHEMBL31693082 | 0.71 | HTT (0.51) | HTTMAP4K4ALDH1A1SMN1; SMN2 | |
| SCHEMBL20331057 | 0.69 | NPC1 (0.69) | NPC1RAB9ACYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20220348573-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-11-03 | — | — | US | disclosed |
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018113584-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | NPC1 4289/4885RAB9A 3622/4885CYP1A1 1190/4885 |
| US-20220348573-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | NPC1 4196/4885RAB9A 3592/4885CYP1A1 959/4885 |
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | NPC1 4289/4885RAB9A 3622/4885CYP1A1 1190/4885 |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | NPC1 4289/4885RAB9A 3622/4885CYP1A1 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.